000129085 001__ 129085
000129085 005__ 20240228143408.0
000129085 0247_ $$2doi$$a10.1007/s00401-016-1545-1
000129085 0247_ $$2pmid$$apmid:27157931
000129085 0247_ $$2ISSN$$a0001-6322
000129085 0247_ $$2ISSN$$a1432-0533
000129085 0247_ $$2altmetric$$aaltmetric:7296684
000129085 037__ $$aDKFZ-2017-05090
000129085 041__ $$aeng
000129085 082__ $$a610
000129085 1001_ $$aLouis, David N$$b0
000129085 245__ $$aThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
000129085 260__ $$aBerlin$$bSpringer$$c2016
000129085 3367_ $$2DRIVER$$aarticle
000129085 3367_ $$2DataCite$$aOutput Types/Journal article
000129085 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524821537_12289
000129085 3367_ $$2BibTeX$$aARTICLE
000129085 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000129085 3367_ $$00$$2EndNote$$aJournal Article
000129085 520__ $$aThe 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.
000129085 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000129085 588__ $$aDataset connected to CrossRef, PubMed,
000129085 7001_ $$aPerry, Arie$$b1
000129085 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b2
000129085 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b3$$udkfz
000129085 7001_ $$aFigarella-Branger, Dominique$$b4
000129085 7001_ $$aCavenee, Webster K$$b5
000129085 7001_ $$aOhgaki, Hiroko$$b6
000129085 7001_ $$0P:(DE-He78)86e3d284d2b1dc72c5965f3b4f909ddb$$aWiestler, Otmar$$b7$$udkfz
000129085 7001_ $$aKleihues, Paul$$b8
000129085 7001_ $$aEllison, David W$$b9
000129085 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-016-1545-1$$gVol. 131, no. 6, p. 803 - 820$$n6$$p803 - 820$$tActa neuropathologica$$v131$$x1432-0533$$y2016
000129085 909CO $$ooai:inrepo02.dkfz.de:129085$$pVDB
000129085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000129085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000129085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)86e3d284d2b1dc72c5965f3b4f909ddb$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000129085 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000129085 9141_ $$y2016
000129085 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000129085 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000129085 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000129085 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000129085 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000129085 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000129085 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000129085 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000129085 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000129085 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000129085 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000129085 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000129085 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000129085 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000129085 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000129085 9201_ $$0I:(DE-He78)M010-20160331$$kM010$$lStiftungsvorstand$$x1
000129085 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x2
000129085 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000129085 980__ $$ajournal
000129085 980__ $$aVDB
000129085 980__ $$aI:(DE-He78)G380-20160331
000129085 980__ $$aI:(DE-He78)M010-20160331
000129085 980__ $$aI:(DE-He78)L401-20160331
000129085 980__ $$aI:(DE-He78)L101-20160331
000129085 980__ $$aUNRESTRICTED